BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Del Trigo M, Bergeron S, Bernier M, Amat-Santos IJ, Puri R, Campelo-Parada F, Altisent OA, Regueiro A, Eigler N, Rozenfeld E, Pibarot P, Abraham WT, Rodés-Cabau J. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet 2016;387:1290-7. [PMID: 27025435 DOI: 10.1016/S0140-6736(16)00585-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 21] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Dinatolo E, Sciatti E, Anker MS, Lombardi C, Dasseni N, Metra M. Updates in heart failure: what last year brought to us. ESC Heart Fail 2018;5:989-1007. [PMID: 30570225 DOI: 10.1002/ehf2.12385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Park JJ, Cho GY, Choi W, Hwang IC, Kim JY, Yoon Y, Yoon CH, Kim BJ, Han MK, Bae HJ. Heart failure and atrial fibrillation in patients with an interatrial shunt. Clin Res Cardiol 2021;110:1270-9. [PMID: 33649885 DOI: 10.1007/s00392-021-01811-4] [Reference Citation Analysis]
3 Kaye DM, Petrie MC, McKenzie S, Hasenfuβ G, Malek F, Post M, Doughty RN, Trochu JN, Gustafsson F, Lang I, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M, Hausleiter J, Raake P, Jondeau G, Bergmann MW, Spelman T, Aytug H, Ponikowski P, Hayward C; REDUCE LAP-HF study investigators. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail 2019;6:62-9. [PMID: 30311437 DOI: 10.1002/ehf2.12350] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
4 Alachkar MN, Alnaimi A, Reith S, Altiok E, Schröder J, Marx N, Almalla M. Incidence and clinical relevance of persistent iatrogenic atrial septal defect after percutaneous mitral valve repair. Sci Rep 2021;11:12700. [PMID: 34135437 DOI: 10.1038/s41598-021-92255-3] [Reference Citation Analysis]
5 Nijenhuis VJ, Sanchis L, van der Heyden JAS, Klein P, Rensing BJWM, Latib A, Maisano F, Ten Berg JM, Agostoni P, Swaans MJ. The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure. Neth Heart J 2017;25:536-44. [PMID: 28741245 DOI: 10.1007/s12471-017-1018-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Hart EA, Zwart K, Teske AJ, Voskuil M, Stella PR, Chamuleau SA, Kraaijeveld AO. Haemodynamic and functional consequences of the iatrogenic atrial septal defect following Mitraclip therapy. Neth Heart J 2017;25:137-42. [PMID: 27896596 DOI: 10.1007/s12471-016-0928-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
7 Schranz D, Akintuerk H, Esmaeili A, Latus H, Apitz C. Heart failure therapy based on interventricular mechanics and cardio-vascular communications. Cardiovasc Diagn Ther 2021;11:1080-8. [PMID: 34527534 DOI: 10.21037/cdt-20-347] [Reference Citation Analysis]
8 Moscarella E, Brugaletta S, Sabaté M. New percutaneous interventions in heart failure. Minerva Cardioangiol 2019;67:145-62. [PMID: 29651826 DOI: 10.23736/S0026-4725.18.04686-8] [Reference Citation Analysis]
9 Olasinska-Wisniewska A, Grygier M. Antithrombotic/Antiplatelet Treatment in Transcatheter Structural Cardiac Interventions-PFO/ASD/LAA Occluder and Interatrial Shunt Devices. Front Cardiovasc Med. 2019;6:75. [PMID: 31231662 DOI: 10.3389/fcvm.2019.00075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rashi Y, Haberman D, Tonchev I, Peretz A, Medvedovsky AT, Gotsman I, Minha S, Poles L, Shimoni S, Goland S, Perlman GY, Danenberg HD, Beeri R, Shuvy M. Pulmonary artery pressures and outcomes after MitraClip. ESC Heart Fail 2020. [PMID: 33085190 DOI: 10.1002/ehf2.13018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Bhardwaj A, Parikh VY, Nair A. Transcatheter Interatrial Shunts for the Treatment of Heart Failure with Preserved Ejection Fraction. International Journal of Cardiovascular Sciences 2021;34:81-8. [DOI: 10.36660/ijcs.20200236] [Reference Citation Analysis]
12 Miyagi C, Miyamoto T, Karimov JH, Starling RC, Fukamachi K. Device-based treatment options for heart failure with preserved ejection fraction. Heart Fail Rev 2021;26:749-62. [PMID: 33432418 DOI: 10.1007/s10741-020-10067-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Bauer A, Esmaeili A, deRosa R, Voelkel NF, Schranz D. Restrictive atrial communication in right and left heart failure. Transl Pediatr 2019;8:133-9. [PMID: 31161080 DOI: 10.21037/tp.2019.04.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Sun W, Zou H, Yong Y, Liu B, Zhang H, Lu J, Shen Y, Li P, Xu T, Chen X, Du A, Jiang M, Hua Y, Sheng Y, Zhou B, Lotan C, Kong X. The RAISE Trial: A Novel Device and First-in-Man Trial. Circ Heart Fail 2022;15:e008362. [PMID: 35378984 DOI: 10.1161/CIRCHEARTFAILURE.121.008362] [Reference Citation Analysis]
15 Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, Gao Q, Hasenfuß G, Kahwash R, Kaye DM, Litwin SE, Lurz P, Massaro JM, Mohan RC, Ricciardi MJ, Solomon SD, Sverdlov AL, Swarup V, van Veldhuisen DJ, Winkler S, Leon MB, Akar J, Ando J, Anzai T, Asakura M, Bailey S, Basuray A, Bauer F, Bergmann M, Blair J, Cavendish J, Chung E, Cikes M, Dauber I, Donal E, Eicher J, Fail P, Flaherty J, Freixa X, Gafoor S, Gertz Z, Gordon R, Guazzi M, Guerrero-miranda C, Gupta D, Gustafsson F, Hadadi C, Hakemi E, Handoko L, Hass M, Hausleiter J, Hayward C, Hickey G, Hummel S, Hussain I, Isnard R, Izumi C, Jondeau G, Juneman E, Kinugawa K, Kipperman R, Krakowiak B, Krim S, Larned J, Lewis G, Lipsic E, Magalski A, Mazimba S, Mazurek J, Mcgrady M, Mckenzie S, Mehta S, Mignone J, Morsli H, Nair A, Noel T, Orford J, Parikh K, Patterson T, Penicka M, Petrie M, Pieske B, Post M, Raake P, Romero A, Ryan J, Saito Y, Sakamoto T, Sakata Y, Samara M, Satya K, Sindone A, Starling R, Trochu J, Upadhya B, van der Heyden J, van Empel V, Varma A, Vest A, Wengenmayer T, Westenfeld R, Westermann D, Yamamoto K, Zirlik A. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)00016-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Harfi TT, Milks MW, Orsinelli DA, Raman SV, Abraham WT, Kahwash R. Imaging Device Therapy: Essentials for the Imager. Heart Fail Clin 2019;15:305-20. [PMID: 30832820 DOI: 10.1016/j.hfc.2018.12.011] [Reference Citation Analysis]
17 Rosalia L, Ozturk C, Shoar S, Fan Y, Malone G, Cheema FH, Conway C, Byrne RA, Duffy GP, Malone A, Roche ET, Hameed A. Device-Based Solutions to Improve Cardiac Physiology and Hemodynamics in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci 2021;6:772-95. [PMID: 34754993 DOI: 10.1016/j.jacbts.2021.06.002] [Reference Citation Analysis]
18 Yi T, Li M, Fan F, Qiu L, Wang Z, Weng H, Shang X, Zhang C, Ma W, Zhang Y, Huo Y. Haemodynamic changes of interatrial shunting devices for heart failure: a systematic review and meta-analysis. ESC Heart Fail 2022. [PMID: 35322588 DOI: 10.1002/ehf2.13911] [Reference Citation Analysis]
19 Raj LM, Saxon LA. Haemodynamic Monitoring Devices in Heart Failure: Maximising Benefit with Digitally Enabled Patient Centric Care. Arrhythm Electrophysiol Rev. 2018;7:294-298. [PMID: 30588319 DOI: 10.15420/aer.2018.32.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Amat-santos IJ, Varela-falcón LH, Abraham WT. Terapias percutáneas en el tratamiento de la insuficiencia cardiaca aguda y crónica: presente y futuro. Revista Española de Cardiología 2017;70:382-90. [DOI: 10.1016/j.recesp.2016.11.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
21 Nishikawa T, Saku K, Uike K, Uemura K, Sunagawa G, Tohyama T, Yoshida K, Kishi T, Sunagawa K, Tsutsui H. Prediction of haemodynamics after interatrial shunt for heart failure using the generalized circulatory equilibrium. ESC Heart Fail 2020;7:3075-85. [PMID: 32750231 DOI: 10.1002/ehf2.12935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Kitamura M, Schmidt T, Kuck KH, Frerker C. Heart Failure Interventions Targeting Impaired Left Ventricles in Structural Heart Disease. Curr Cardiol Rep 2018;20:8. [PMID: 29435772 DOI: 10.1007/s11886-018-0950-6] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Afari ME, Syed W, Tsao L. Implantable devices for heart failure monitoring and therapy. Heart Fail Rev 2018;23:935-44. [PMID: 29524066 DOI: 10.1007/s10741-018-9687-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 Paitazoglou C, Bergmann MW. The atrial flow regulator: current overview on technique and first experience. Ther Adv Cardiovasc Dis 2020;14:1753944720919577. [PMID: 32972299 DOI: 10.1177/1753944720919577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kaye DM, Nanayakkara S. Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med 2019;6:143. [PMID: 31620452 DOI: 10.3389/fcvm.2019.00143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
26 Guimaraes L, Del Val D, Bergeron S, O'Connor K, Bernier M, Rodés-Cabau J. Interatrial Shunting for Treating Acute and Chronic Left Heart Failure. Eur Cardiol 2020;15:e18. [PMID: 32419849 DOI: 10.15420/ecr.2019.04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Ahmad U, Lilly SM. Interventional Heart Failure and Hemodynamic Monitoring. Heart Fail Clin 2018;14:625-34. [PMID: 30266370 DOI: 10.1016/j.hfc.2018.06.007] [Reference Citation Analysis]
28 Lu D, Zhu J, Liao B. Efficacy and Safety of Inter-Atrial Shunt Devices for Heart Failure With Reduced or Preserved Ejection Fraction: Early Experiences. Heart Lung Circ 2018;27:359-64. [PMID: 28483550 DOI: 10.1016/j.hlc.2017.02.027] [Reference Citation Analysis]
29 Luani B, Groscheck T, Genz C, Tanev I, Rauwolf T, Herold J, Medunjanin S, Schmeisser A, Braun-Dullaeus RC. Left atrial enlargement and clinical considerations in patients with or without a residual interatrial shunt after closure of the left atrial appendage with the WATCHMAN™-device. BMC Cardiovasc Disord 2017;17:294. [PMID: 29233088 DOI: 10.1186/s12872-017-0728-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cuthbert JJ, Pellicori P, Clark AL. Interatrial shunt devices for heart failure with normal ejection fraction: a technology update. Med Devices (Auckl) 2017;10:123-32. [PMID: 28652826 DOI: 10.2147/MDER.S113105] [Reference Citation Analysis]
31 De Rosa R, Schranz D. Creation of a restrictive atrial left-to-right shunt: a novel treatment for heart failure. Heart Fail Rev 2018;23:841-7. [PMID: 30267205 DOI: 10.1007/s10741-018-9741-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
32 Lurz P, Unterhuber M, Rommel KP, Kresoja KP, Kister T, Besler C, Fengler K, Sandri M, Daehnert I, Thiele H, Blazek S, von Roeder M. Iatrogenic Atrial Septal Defects Following Transcatheter Mitral Valve Repair and Implications of Interventional Closure. JACC Cardiovasc Interv 2021;14:2685-94. [PMID: 34949392 DOI: 10.1016/j.jcin.2021.09.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Griffin JM, Borlaug BA, Komtebedde J, Litwin SE, Shah SJ, Kaye DM, Hoendermis E, Hasenfuß G, Gustafsson F, Wolsk E, Uriel N, Burkhoff D. Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. J Am Heart Assoc 2020;9:e016760. [PMID: 32809903 DOI: 10.1161/JAHA.120.016760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Hasenfuß G, Jacobshagen C. [InterAtrial Shunt Device in diastolic heart failure]. Internist (Berl) 2018;59:1054-62. [PMID: 30194481 DOI: 10.1007/s00108-018-0484-4] [Reference Citation Analysis]
35 Maier RK, Menon D, Stafinski T. The Medical Devices Special Access Program in Canada: A Scoping Study. Healthc Policy 2018;13:40-57. [PMID: 29595436 DOI: 10.12927/hcpol.2018.25398] [Reference Citation Analysis]
36 Kaye DM, Hasenfuß G, Neuzil P, Post MC, Doughty R, Trochu JN, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M, Walton A, Muller D, Walters D, Hausleiter J, Raake P, Petrie MC, Bergmann M, Jondeau G, Feldman T, Veldhuisen DJ, Ponikowski P, Silvestry FE, Burkhoff D, Hayward C. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 2016;9:e003662. [PMID: 27852653 DOI: 10.1161/CIRCHEARTFAILURE.116.003662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 24] [Article Influence: 12.6] [Reference Citation Analysis]
37 Burlacu A, Simion P, Nistor I, Covic A, Tinica G. Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review. Heart Fail Rev 2019;24:793-803. [DOI: 10.1007/s10741-019-09787-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]